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The mechanisms underlying the immunopathology of tuberculous meningitis (TBM), the most severe clinical form of
extrapulmonary tuberculosis (TB), are not understood. It is currently believed that the spread of Mycobacterium tuberculosis
(Mtb) from the lung is an early event that occurs before the establishment of adaptive immunity. Hence, several innate immune
mechanisms may participate in the containment of Mtb infection and prevent extrapulmonary disease manifestations. Natural
killer (NK) cells participate in defensive processes that distinguish latent TB infection (LTBI) from active pulmonary TB (PTB).
However, their role in TBM is unknown. Here, we performed a cross-sectional analysis of circulating NK cellCID="C008"
value="s" phenotype in a prospective cohort of TBM patients (n = 10) using ﬂow cytometry. Also, we addressed the responses of
memory-like NK cell subpopulations to the contact with Mtb antigens in vitro. Finally, we determined plasma levels of soluble
NKG2D receptor ligands in our cohort of TBM patients by enzyme-linked immunosorbent assay (ELISA). Our comparative
groups consisted of individuals with LTBI (n = 11) and PTB (n = 27) patients. We found that NK cells from TBM patients
showed lower absolute frequencies, higher CD69 expression, and poor expansion of the CD45RO+ memory-like subpopulation
upon Mtb exposure in vitro compared to LTBI individuals. In addition, a reduction in the frequency of CD56brightCD16- NK
cells characterized TBM patients but not LTBI or PTB subjects. Our study expands on earlier reports about the role of NK cells
in TBM showing a reduced frequency of cytokine-producing cells compared to LTBI and PTB.
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1. Introduction
Mycobacterium tuberculosis (Mtb), the causative agent of
tuberculosis (TB), remains the leading cause of death associated with a single pathogen [1]. Approximately a quarter of
the world population has latent TB infection (LTBI) [2],
and 10% of the infected individuals are at risk of developing
active pulmonary TB (PTB) [1]. The limited protective eﬀectiveness of the bacillus Calmette-Guerin (BCG) TB vaccine
contributes to this global crisis. Moreover, the broad clinical
spectrum of TB delays the diagnosis and initiation of antibiotic therapy, thus impeding an adequate control of Mtb
transmission. In this regard, diﬀerent clinical scenarios can
result from human-Mtb interactions. As mentioned above,
90% of infected humans with LTBI develop adaptive immune
responses that control but do not eliminate Mtb, remaining
asymptomatic. Another group of Mtb-infected individuals
cannot establish or maintain protective immune mechanisms, thus progressing to active PTB. From these, most individuals manifest clinical data of Mtb infection limited to the
lung, whereas in a small group of TB patients, the bacillus
spreads to extrapulmonary organs [3].
Tuberculous meningitis (TBM) is the most severe form of
extrapulmonary TB due to its high morbidity and mortality
rates [4]. Unfortunately, the factors controlling the Mtb dissemination into the central nervous system (CNS) and the
immunopathology of TBM are not completely deﬁned [5].
The current understanding of the immune determinants of
the clinical outcome of TB is based on the study of T cell
adaptive immune responses. This approach has revealed
novel correlates of protection which do not always provide
sterilizing immunity in animal models and have shown low
prognostic value to predict disease progression in LTBI individuals [6, 7]. More recently, targeting diverse components of
the innate immune system has emerged as an attractive
approach for TB vaccine development [8–11]. This strategy
is based on novel discoveries about the importance of speciﬁc
myeloid cell subtypes and innate lymphoid cell (ILC) subsets
for protective immunity against Mtb.
NK cells are innate lymphocytes that exert cytotoxic and
cytokine-production activities and can mediate recall
responses against previously recognized stimuli, resembling
memory lymphocytes [12]. Therefore, these cells are crucial
for immune responses against several pathogens, including
Mtb [9, 13]. NK cells inﬁltrate the lungs of PTB patients
and can respond to contact with the bacillus in vitro [14–
18]. In animal TB models, these cells can compensate for
the absence of adaptive lymphocytes, mediating early eﬀector
activities that control the pulmonary infection with Mtb [19].
Several phenotypical and functional deﬁciencies are displayed by peripheral NK cells from PTB patients compared
to LTBI individuals, supporting a role for NK cells in
defenses against pulmonary Mtb [15, 20–24]. Strikingly,
NK cell subsets with adaptive properties expand in mice, primates, and humans with TB, making them potential targets
for vaccines [25–28]. However, the phenotype and function
of NK cells in TB patients that develop extrapulmonary disease manifestations, including TBM, has not been extensively
addressed. This is important, since the dissemination of Mtb
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is an early event during which NK cells and other innate
immune cells may participate [29].
Here, we characterized the immunophenotype of circulating NK cells in patients with TBM and compared it with
LTBI and PTB subjects. Our results provide novel insights
into the role of NK cells in immunity against Mtb.

2. Materials and Methods
2.1. Human Participants. We conducted a prospective study
in adult patients with acute TBM that attended and were
admitted to the Neuroinfectology Department of the Instituto Nacional de Neurología y Neurocirugía Manuel Velasco
Suarez (INNyN), in Mexico City, from January of 2017 to
December of 2018. Only those individuals that met the clinical criteria for probable or deﬁnitive TBM, according to the
case deﬁnition established in Cape Town, South Africa, in
2009 [30], were eligible.
Peripheral blood samples were obtained from enrolled
participants on admission. Our comparative cohorts
included LTBI and PTB patients recruited at the TB clinic
of the Instituto Nacional de Enfermedades Respiratorias
Ismael Cosío Villegas (INER), in Mexico City. The LTBI
group included healthy close contacts of PTB patients with
positive results in the QuantiFERON®-TB Gold Plus test
(QIAGEN, Hilden, Germany). The PTB group included
patients with laboratory-conﬁrmed TB diagnosis by positive
results in sputum smear microscopy, sputum/bronchoalveolar lavage (BAL) culture, and GeneXpert MTB/RIF test
(Cepheid, CA, USA). A group of age- and sex-matched
healthy volunteer donors was recruited and considered as
controls (HC).
Solid-organ transplant recipients and patients with
human immunodeﬁciency virus (HIV) infection, receiving
immunosuppressive treatment, diagnosed with cancer, diabetes, or autoimmune diseases, were excluded from the
study. Clinical and demographic data from participants were
obtained by direct clinical interview, physical examination,
and review of their medical records.
2.2. Sample Processing. Peripheral blood mononuclear cells
(PBMCs) were isolated by centrifugation gradient using
Ficoll-Paque™ PLUS (GE Healthcare, Life Sciences, PA,
USA) as described before. Plasma aliquots for protein determinations were stored at -80°C until use.
2.3. In Vitro Assays. Freshly isolated PBMCs from HC, LTBI,
PTB, and TBM individuals were exposed to Mtb antigens
in vitro as previously described [15]. Brieﬂy, cells were plated
at a density of 2:5 × 106 cells per mL in complete Roswell
Park Memorial Institute (RPMI-1640) medium supplemented with 2 mM L-glutamine and 10% fetal bovine serum
(FBS) and cultured with 25 μg/mL of a cell wall (CW) extract
of Mtb H37Rv at 37°C, 5% CO2, for 48 hours. The H37Rv
CW preparation was gently provided by Dr. Shabaana A.
Khader, from the Department of Molecular Microbiology,
Washington University School of Medicine in St Louis,
MO, USA.
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2.4. Flow Cytometry. Freshly isolated or Mtb H37Rv CWstimulated PBMCs were stained with appropriate dilutions
of the following speciﬁc ﬂuorochrome-labeled antibodies:
BV510 anti-human CD3 (OKT3, BioLegend, USA), BV510
anti-human CD14 (M5-E2, BioLegend, USA), PerCP antihuman CD56 (HCD56, BioLegend, USA), APC/Cy7 antihuman CD16 (3G8, BioLegend, USA), APC anti-human
NKG2D (1D11, BioLegend, USA), PE anti-human NKp46
(9E2, BioLegend, USA), BV421 anti-human CD69, (FN50,
BioLegend, USA), FITC anti-human CD45RO (UCHL1, BioLegend, USA), and AlexaFluor700™ anti-human CD27
(O323, 302814, USA). After staining, samples were washed
with Cell Staining Buﬀer (BioLegend, 420201, USA), resuspended in 4% paraformaldehyde, and acquired in a BD
FACS™ Aria II cytometer (BD Biosciences, USA) using
FACSDiva software. Tubes with microbeads (Anti-Mouse
Ig, κ/Negative Control Compensation Particles Set, BD™
CompBead, BD Biosciences, USA) were stained with single
ﬂuorochrome-labeled antibodies and served to set a compensation matrix. Cells were gated based on their forward/side scatter characteristics and a ﬂuorescence minus one
(FMO) control for each speciﬁc marker. Human NK cells
were deﬁned as CD3-CD14-CD56+. We acquired at least 1
× 104 CD3-CD14-CD56+ NK cells from each sample. The
compensation set up and calculation of the frequency of speciﬁc cell subsets were made using FlowJo (FlowJo, LLC, Ashland, OR, USA).
2.5. Plasma Protein Quantiﬁcations. Plasma levels of MHC
class I polypeptide-related sequence A (MIC-A), MHC class
I polypeptide-related sequence B (MIC-B), and UL16 binding protein 1 (ULBP-1) were determined by enzyme-linked
immunosorbent assay (ELISA) using commercial kits
(MBS175982, MBS177192, and MBS3800229, MyBioSource,
USA), and following the manufacturer’s instructions.
2.6. Study Approval. The current study was reviewed and
approved by the Institutional Review Board of the INER
(project number B04-15) and the Ethics Committee of the
INNyN (project number 160/16) in Mexico City. All patients
or their legal guardians provided written consent to participate in the study. Blood samples were processed and stored
according to the Mexican Constitution law NOM-012SSA3-2012, which establishes criteria for executing clinical
research projects in humans.
2.7. Statistical Analysis. Descriptive statistics were used to
characterize the study population clinically. Speciﬁc tests
are mentioned in ﬁgure and table legends. Statistical analyses
were performed using GraphPad Prism 8 (La Jolla, CA,
USA). Two-tailed p values ≤ 0.05 were considered as signiﬁcant: ∗ p ≤ 0:05, ∗∗ p ≤ 0:01, ∗∗∗ p ≤ 0:001, and ∗∗∗∗ p ≤ 0:0001.

3. Results
3.1. Participant Characteristics. TBM is an infrequent but
severe complication of extrapulmonary TB [4]. As such, we
were able to recruit only ten patients with TBM over two
years for the present study. From these patients, six were
females and four males, with a median age of 35 years. Our
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comparative cohorts consisted of 27 patients with active
PTB and 11 individuals with LTBI. Their main clinical features are summarized in Table 1. Thirty-seven percent of
PTB participants were infected with multi-drug resistant
(MDR) Mtb strains. Meanwhile, four patients in the TBM
group met the criteria for a deﬁnitive disease, as the infection
was conﬁrmed by positive culture of cerebrospinal ﬂuid
(CSF). The remaining six patients were categorized as probable TBM, according to their clinical, radiological, and laboratory test characteristics [30], which are further described in
Table 2. Enrolled patients with probable and deﬁnitive TBM
presented meningeal signs (70%), fever (50%), motor deﬁcit
(50%), sensitive deﬁcit (30%), and cranial nerve palsies
(30%) as their main clinical manifestations. Also, TBM
patients typically showed lymphocytic pleocytosis, low glucose levels, elevated proteins, and increased adenosine deaminase (ADA) in the CSF analysis, as well as vasculitis,
hydrocephalus, and basal meningeal enhancement in the
brain magnetic resonance imaging (MRI; see Table 2). Two
TBM patients died due to severe neurological manifestations.
Interestingly, most recruited participants with meningitis
denied a history of PTB, and chest X-ray images obtained
at hospital admission showed no lung involvement in six
TBM patients. This supports a possible neurotropism of
some Mtb strains, as suggested before [31].
3.2. Peripheral NK Cell Subpopulations in TBM Patients. Previous investigations addressing the role of NK cells in human
TB have revealed phenotypical deﬁciencies in PTB patients
compared to LTBI individuals [15, 20–24], suggesting the
protective participation of NK cells during pulmonary Mtb
infection. However, little evidence exists about the phenotype
of these cells in patients with extrapulmonary manifestations
of the disease. Here, we focused part of our study on determining the relative frequency of some of the main NK cell
subpopulations in humans with TBM and made a comparison with LTBI and PTB subjects. For this purpose, we use
ﬂow cytometry in PBMC samples obtained from all study
participant groups. Figure 1(a) shows the gating strategy used
for enumerating NK cells.
Our analyses showed no diﬀerences in the percentage of
total lymphocytes in PBMCs between groups (Figure 1(b)).
Strikingly, NK cells were signiﬁcantly less abundant in
TBM patients (3.57%, 1.83%-5.42%, interquartile range
[IQR]) compared to LTBI individuals (6.95%, 4.07%-9.28%,
IQR, p = 0:0232). Similarly, PTB patients also showed lower
percentages of total NK cells (3.7%, 2.57%-6.13%, IQR) than
LTBI subjects (p = 0:0074; Figures 1(c) and 1(d)). These ﬁndings coincide with previous reports of diminished amounts of
total NK cells as a hallmark of active pulmonary Mtb infection in humans [15, 20–24]. Hence, our results demonstrate
that circulating NK cells are also depleted from the circulation in patients with extrapulmonary manifestations of TB,
like TBM.
One of the principal alterations observed in PTB patients
is the reduced frequency of CD56brightCD16- NK cells in the
peripheral blood [23]. This subpopulation is characterized by
a lower maturation state and a higher capacity to produce
cytokines upon stimulation [32]. We also analyzed the
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Table 1: Participant characteristics.
LTBI (n = 11)
A

PTB (n = 27)
B

TBM (n = 10)
C

A vs. B

p values
A vs. C

B vs. C

42 (19-80)

43 (18-67)

35 (21-52)

0.8458

0.4159

0.5831

8 (72.72)
3 (27.27)

14 (51.85)
13 (48.14)

6 (60.0)
4 (40.0)

0.2960

0.6594

0.7246

Weight, mean (SD)

70.91 (16.57)

54.41 (9.60)

71.39 (12.91)

0.0019

0.9816

0.0008

Height, mean (SD)

1.58 (0.08)

1.62 (0.08)

1.64 (0.09)

0.2572

0.2660

0.7416

BMI, mean (SD)

28.25 (5.71)

20.59 (3.59)

26.09 (3.88)

<0.0001

0.3369

0.0061

Drug resistance
MDR, n (%)
Sensitive, n (%)
Undetermined, n (%)

ND
ND
ND

10 (37.03)
14 (51.85)
3 (11.11)

ND
ND
ND

—
—
—

—
—
—

—
—
—

MTB case category
Deﬁnitive, n (%)
Probable, n (%)

N/A
N/A

N/A
N/A

4 (40.0)
6 (60.0)

—
—

—
—

—
—

0 (0.0)
11 (100.0)

0 (0.0)
27 (100.0)

2 (20.0)
8 (80.0)

—
—

—
—

—
—

Characteristic
Median age (range)
Gender
Female, n (%)
Male, n (%)

Outcome
Deceased, n (%)
Survived, n (%)

Diﬀerences between groups were estimated using the chi2 or Mann-Whitney U test, as appropriate. LTBI: latent tuberculosis infection; MDR: multidrug
resistant; MTB: meningeal tuberculosis; N/A: not applicable; ND: not determined; PTB: active pulmonary tuberculosis; SD: standard deviation.

frequency of these cells in our cohorts of TB patients. As
expected, the percentages of CD56brightCD16- NK cells were
slightly lower in PTB (2.75%, 2.11%-3.73%, IQR) than those
in LTBI subjects (3.76%, 2.9%-4.06%, IQR), although the difference did not reach statistical signiﬁcance (Figures 1(e) and
1(f)). Remarkably, CD56brightCD16- NK cells were diminished
in TBM patients (1.32%, 0.69%-2.15%, IQR) compared to
LTBI (p = 0:0025) and PTB patients (p = 0:0331). Conversely,
the TBM group diﬀered from the rest of the participants
regarding their higher percentages of NK cells belonging to
the CD56dimCD16+ subpopulation (Figure 1(g)). These cells
are mature and possess an intrinsic cytotoxic function [32].
Of note, the percentage of CD56dimCD16+ correlated with
the body mass index (BMI) of TBM patients (Figure S1).
Together, our results show that CD56brightCD16- NK
cells are reduced in the circulation of TBM patients, and such
a reduction is more signiﬁcant than in PTB subjects (1.32%,
0.69%-2.15%, IQR vs. 2.75%, 2.11%-3.73%, IQR, p = 0:0331
). These ﬁndings may also indicate an active mobilization of
NK cells from the circulation to the sites of infection in
TBM patients. Therefore, we evaluated the expression of
the activation and tissue-homing marker CD69 in peripheral
NK cells [33]. Notably, we found a signiﬁcantly higher percentage of CD69+ NK cells in TBM patients (8.34%, 5.64%11.8%, IQR) compared to HC (2.24%, 1.89%-2.77%, IQR, p
= 0:0025) and a slight diﬀerence with respect to LTBI individuals (4.38%, 2.23%-5.4%, IQR, p = 0:0737; Figures 2(a)
and 2(b)). Furthermore, NK cells from TBM patients showed
a higher CD69 mean ﬂuorescence intensity (MFI) than LTBI
subjects (p < 0:05; Figure 2(c)). Similar observations were

made in PTB patients, whereas there were no diﬀerences in
the MFI and the percentage of CD69+ NK cells between
TBM and PTB groups.
We also compared the phenotype of circulating NK
cells between probable and deﬁnite TBM patients, since
both groups might diﬀer in Mtb burden and thus detectability of the infection. We found that patients with deﬁnite
disease showed reduced frequencies of CD56dimCD16+
NK cells (Figure S1). Meanwhile, no diﬀerences in total,
CD56brightCD16-, and CD69+ NK cells were observed
between TBM patients. Also, no correlations between NK
cell subsets and prognostic variables such as the Glasgow
Coma Scale (GCS) and British Medical Research Council
stage at admission were observed (Figure S1).
3.3. Expression of Surface-Activating Receptors in Peripheral
NK Cells. A variety of activating and inhibitory receptors
govern the functions of NK cells [34]. Some of these receptors
allow NK cells to recognize pathogen-associated molecular
patterns (PAMPs) and exert eﬀector functions against infective agents [17, 35, 36]. As such, the deﬁcient expression of
activating receptors may limit the capacity of NK cells to
respond during infections. Thus, we also evaluated the
expression of activating NK cell receptors in our patients to
determine if the lower control and higher severity of infection
in TBM patients were related to possible phenotypical alterations of NK cells.
First, we analyzed the expression of the natural killer cell
p46-related protein (NKp46) receptor, which is a member of
the natural cytotoxicity receptor (NCR) family. NKp46
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Table 2: Clinical and laboratory characteristics of TBM patients.
Characteristic
Clinical manifestations
Fever
Meningeal signs
Focal deﬁcit
Motor
Sensitive
Cognitive decline
Duration of symptoms (days)
GCS on admission, median (range)
BMRC stage, median (range)
History of PTB
Abnormal chest X-ray
CSF analysis
Leukocytes (cells/mm3)
Neutrophils (%)
Lymphocytes (%)
Glucose (mg/dL)
Proteins (mg/dL)
ADA (U/L)
Positive culture
Brain MRI
Vasculitis
Hydrocephalus
Basal meningeal enhancement

N = 10
5 (50)
7 (70)
6 (60)
5 (50)
3 (30)
3 (30)
44 (31–68)
14 (7–15)
1 (0–3)
2 (20)
4 (40)
256.5 (30.75–614.5)
4 (2.2–7.0)
95.5 (51–99)
40 (24–44)
100 (66–198)
11 (2.2–17.7)
2 (20)
4 (40)
2 (20)
6 (60)

Data are displayed as median (IQR) or n (%). ADA: adenosine deaminase;
BMRC: British Medical Research Council; CSF: cerebrospinal ﬂuid; CT:
computed tomography; GCS: Glasgow Coma Scale; MRI: magnetic
resonance imaging; PTB: pulmonary tuberculosis; TBM: tuberculous
meningitis.

mediates the recognition and lysis of Mtb-infected human
monocytes after binding to vimentin [37]. Thus, a deﬁciency
in the expression of NKp46 may render NK cells incapable of
eliminating intracellular reservoirs of Mtb infection. Interestingly, we found a reduction of NKp46+ NK cells in the LTBI
and PTB groups compared to HC, which coincides with a
previous report describing signiﬁcant downregulation of
NKp46 in LTBI individuals [38]. However, we did not
observe any diﬀerence in the percentage of NKp46+ NK cells
relative expression of this marker between TBM, PTB, and
LTBI patients (Figures 3(a)–3(c)). We also compared the
expression of the natural killer group 2 member D (NKG2D)
C-type lectin-like receptor between participant groups. This
molecule mediates the recognition and elimination of Mtbinfected monocytes upon attachment to the ULBP-1 ligand
on their surface [18]. As for NKp46, NKG2D+ NK cells were
more abundant in HC, but we did not ﬁnd any diﬀerence in
the percentage of NKG2D+ NK cells and the relative expression of this molecule between TBM patients and the other TB
groups (Figures 3(d)–3(f)).
These ﬁndings suggest that diﬀerences in TB disease susceptibility are not related with deﬁciencies in the expression
of NKp46 and NKG2D. Hence, the participation of NK cells

during TBM, if any, is not dependent on NKp46- and
NKG2D-mediated cytotoxicity against infected phagocytes
in vivo. This is in sharp contrast with evidence of the Mtbinduced upregulation of ligands for activating NK cell receptors in infected cells in vitro. For instance, as mentioned
above, human monocytes infected with Mtb increase the
expression of the NKG2D receptor ligand ULBP-1 [18]. Similarly, Mtb-infected dendritic cells (DCs) also upregulate the
molecule MIC-A in their surface [39], which is also recognized by NKG2D. Interestingly, a lower frequency of both
NKp46+ and NKG2D+ NK cells was found in patients with
deﬁnite but not probable TBM (Figure S1). This ﬁnding
might imply that deﬁciencies in the expression of activating
receptors are related to higher Mtb burden among TBM
patients despite not being associated with higher risk of
disseminated disease in the overall TB population.
Infected and malignant cells can escape from the activity
of NKG2D by shedding these ligands [40], which then act as
decoy molecules that inactivate the cytotoxic capacity of NK
cells. These soluble products may become detectable in the
serum. To address whether this mechanism of immune evasion is employed by Mtb and operates during TBM, we measured the serum levels of three diﬀerent soluble NKG2D
receptor ligands: ULBP-1, MIC-A, and MIC-B. Of note, we
found high serum levels of ULBP-1 only among PTB patients
(4380 pg/mL, 3015 pg/mL–5538 pg/mL, IQR), but not in HC
(2715 pg/mL, 2182 pg/mL–3640 pg/mL, IQR, p = 0:0178),
LTBI (2729 pg/mL, 1929 pg/mL–3666 pg/mL, IQR, p =
0:0055), and TBM individuals (2847 pg/mL, 2198 pg/mL–
4120 pg/mL, IQR, p = 0:0364; Figure 4(a)). In contrast, there
were no diﬀerences in the levels of MIC-A and MIC-B
between all participant groups (Figures 4(b) and 4(c)).
These observations indicate that the evasion of NK cell
cytotoxicity through the shedding of ULPB-1 from infected
phagocytes may be an important mechanism in the pathogenesis of PTB but not TBM. However, we cannot rule
out the participation of this phenomenon inside the Mtbinfected brain during TBM, as we did not explore the CSF
levels of these ligands. Collectively, our results suggest that
NK cell responses are diﬀerentially regulated during TBM,
PTB, and LTBI.
3.4. Memory-Like NK Cells in Humans with TBM. A striking
functional property of NK cells is their ability to mediate secondary responses against antigenic and nonantigenic stimuli,
resembling memory of adaptive lymphocytes. This mechanism provides protection against viruses in mice and might
participate in immunity to human infections [12]. Indeed,
several subpopulations of memory-like NK cells might get
involved in the mechanisms of defense during TB [8, 9].
For instance, BCG-vaccinated mice display an IL-21 dependent expansion of CD27+ NK cells that mediate protective
memory-like responses against Mtb [27]. These CD27+ NK
cells are also expanded in LTBI patients but not healthy individuals and proliferate upon in vitro exposure to Mtb.
To address whether CD27+ NK cells are relevant during
TBM, we determined the relative frequency of these cells in
the circulation of our study participants. However, we did
not ﬁnd diﬀerences in the percentage of circulating CD27+

6

Journal of Immunology Research
Singlets

Lymphocytes
250K

200K

200K

150K

150K

100K

100K

50K

50K

0

0
100K

0

200K

NK cells FMO

104
103
CD56

250K

100K

0

0
101

200K

103

105

CD3/CD14

(a)

% of total lymphocytes from PBMCs

100

80

60

40

20

0
HC

LTBI

PTB

TBM

(b)
LTBI

PTB

TBM

NK cells
104

10.5

104

5.39

103

103

103

0

0

0

101

103

105

101

103

105

CD3/CD14

(c)
⁎⁎
⁎

18
% of NK cells from total lymphocytes

CD56

104

⁎

16
⁎⁎

14
⁎⁎⁎⁎

12
10
8
6
4
2
0
HC

LTBI

PTB

(d)

Figure 1: Continued.

TBM

1.83

101

103

105

Journal of Immunology Research

7

(e)
⁎⁎

14

⁎⁎

⁎⁎

100
% of CD5dimCD16+ NK cells

12
% of CD56brightCD16-NK cells

120

10
⁎
8
6
4

80
60
40
20

2

0

0
HC

LTBI

PTB

TBM

HC

(f)

LTBI

PTB

TBM

(g)

Figure 1: Major NK cell subpopulations in patients with TBM. (a) Flow cytometry gating strategy for the analysis of circulating NK cells in
peripheral blood mononuclear cell (PBMC) samples from healthy controls (HC, n = 10), individuals with latent TB infection (LTBI, n = 11),
patients with active pulmonary TB (PTB, n = 27), and patients with tuberculous meningitis (TBM, n = 10). (b) Percentage of lymphocytes
from total PBMCs. (c, d) Percentage of NK cells from total lymphocytes. (e) Analysis of major NK cell subpopulations in the blood. (f)
Percentage of CD56brightCD16- NK cells. (g) Percentage of CD56dimCD16+ NK cells. Diﬀerences between groups were analyzed using the
Kruskal-Wallis test and the post hoc Dunn’s test for multiple comparisons. The data shown represent the mean (±SE) values. ∗ p ≤ 0:05,
∗∗
p ≤ 0:01, and ∗∗∗ p ≤ 0:001.

NK cells between HC, LTBI, PTB, and TBM patients
(Figure 5(a)). We also compared the in vitro responses of
CD27+ NK cells against the contact with a CW extract of
Mtb H37Rv. As previously reported [27], we found that cells
from LTBI, but not healthy individuals, proliferate upon
exposure to Mtb antigens (Figure 5(b)). CD27+ NK cells also
expanded in PTB and TBM, although to a lower level than
LTBI individuals. Interestingly, CD27+ NK cells expressed
the activation and tissue-homing marker CD69 with higher
frequency than CD27- NK cells in all participant groups
(Figure 5(c)). This ﬁnding suggests that CD27+ NK cells have
an intrinsic higher capacity to respond to Mtb antigens, but
their responsiveness is similar in PTB and TBM patients.
Hence, these data indicate that CD27+ NK cells might not
be relevant for protection against extrapulmonary manifestations of TB, such as TBM.
Another subgroup of adaptive NK cells that express the
memory marker CD45RO has been isolated from the pleural
ﬂuid of individuals with tuberculous pleural eﬀusion [25, 26].
These cells show increased cytotoxic and cytokine production capacity in response to IL-12 and BCG as compared to
their CD45RO- counterpart. As for CD27+ NK cells, we also

compared the frequency of CD45RO+ NK cells in the blood
of HC and subjects with LTBI, PTB, and TBM. This analysis
showed no diﬀerences in the percentage of CD45RO+ NK
cells between all participant groups (Figure 5(d)), although
CD45RO+ NK cells were more abundant in the blood of
patients with deﬁnite but not probable TBM (Figure S1).
Remarkably, after an in vitro stimulation with Mtb H37Rv
CW, an expansion of CD45RO+ NK cells was observed
only among LTBI individuals but not patients with PTB
and TBM (Figure 5(e)). Moreover, a higher percentage of
CD45RO+ NK cells expressed CD69 than CD45RO- NK
cells in response to Mtb antigens in all participants
(Figure 5(f)). Collectively, these data indicate that
memory-like CD45RO+ NK cells respond to Mtb antigens
and may play a protective role during TB. However, the
responses of these cells do not impact the risk of
progression of PTB to TBM.

4. Discussion
TB of the CNS encompasses a spectrum of manifestations
that includes meningitis, parenchymal tuberculomas,

8

Journal of Immunology Research

SSC-A

Gated on
NK cells

LTBI

PTB

TBM

250K

250K

250K

200K

200K

200K

150K

150K

150K

100K

100K

100K

1.93

50K

22.7

50K

0

0
103

0

105

17.0

50K
0

0

105

103

0

103

105

CD69
(a)

⁎
⁎⁎

80
60
40
30

⁎⁎⁎

5000

⁎⁎

⁎⁎
⁎⁎⁎⁎

4000
CD69 MFI

% of CD69+ NK cells

⁎

20

10

3000
2000
1000

0

0
HC

LTBI

PTB

TBM

(b)

HC

LTBI

PTB

TBM

(c)

Figure 2: Expression of CD69 in peripheral NK cells from patients with TB. (a) The expression of CD69 in peripheral blood NK cells from
healthy controls (HC, n = 10), individuals with latent TB infection (LTBI, n = 11), patients with active pulmonary TB (PTB, n = 27), and
patients with tuberculous meningitis (TBM, n = 10) was assessed by ﬂow cytometry. (b) Percentage of CD69+ NK cells. (c) Mean
ﬂuorescence intensity (MFI) values for CD69 in NK cells. Diﬀerences between groups were analyzed using the Kruskal-Wallis test and
post hoc Dunn’s test for multiple comparisons. The data shown represent the mean (±SE) values. ∗ p ≤ 0:05 and ∗∗∗ p ≤ 0:001.

tuberculous abscesses, and vasculitis. These entities are characterized by an intense inﬂammatory response that can cause
severe nervous tissue damage [4, 5]. TBM is the most devastating form of extrapulmonary TB due to its high mortality
and neurological sequela. Despite this, the immunopathogenesis of TBM is not completely understood so far. Much
of what is currently known relies on descriptions made by
Rich and McCordock almost a century ago [41]. These
researchers proposed that Mtb could reach the CNS a long
time before infected individuals manifest symptoms remaining silent within the brain. Nonetheless, the route and mechanisms by which Mtb invades the human brain remained
unclear for many years until recent advances were achieved
using in vitro assays and animal models [42–44].
The CNS is separated from the systemic circulation by
the blood-brain barrier (BBB) and the blood-cerebrospinal
ﬂuid barrier (BCSFB). These barriers limit the access of circulating substances and infectious agents to the nervous system
[45]. Nevertheless, certain neuroinfectious pathogens have
virulence factors that allow them to adhere to the endothelium and cross the BBB [46, 47]. Indeed, some clinical strains

of Mtb isolated from humans with TBM can cause CNS
infection after intratracheal inoculation to mice [31]. Also,
in vitro assays have demonstrated that Mtb can cross the
BBB via transcytosis [42]. The pathogen might also enter
the brain as free mycobacteria or inside an infected monocyte
[43, 44], and speciﬁc cytokines induced during the infection
might make BBB more permeable to Mtb [46, 47].
Along with these mechanisms, the dissemination of TB to
the CNS also depends on lung defenses’ ability to control the
initial infection. Indeed, some investigations suggest that the
spread of Mtb to extrapulmonary organs is a silent and very
early event that precedes the initiation of antigen-speciﬁc
adaptive immune responses in the lung [29]. Hence, the
function of a plethora of innate defense mechanisms might
determine the disease’s course and progression. Among these
innate components of immunity, NK cells play a relevant role
during PTB. Their participation and speciﬁc eﬀector functions that improve the control of Mtb have been extensively
revised elsewhere [8, 9, 13]. Despite this, little literature exists
on the role of NK cells in the brain inﬂammatory response
associated with TBM. This is in part related to the lack of
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Figure 3: Expression of activating receptors in peripheral blood NK cells from patient with TBM. (a) Analysis of the expression of NKp46 in
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animal models that mimic the spread of pulmonary TB to the
CNS since those that exist use the intracranial or intravenous
route to inoculate the pathogen into the brain [48]. Furthermore, due to the low frequency and complicated diﬀerential
diagnosis of the disease, samples from humans with TBM
are scarcely available to be analyzed at the early stages of
infection.
NK cells might play a role in the pathogenesis of diﬀerent
viral and bacterial infections of the CNS. In some cases, such
as brain infection with herpes viruses, the activity of NK cells
is protective [49, 50]. As such, children with functional and
genetic deﬁciencies in NK cells are susceptible to herpetic
encephalitis [49], while mice completely deployed of NK
cells and T cells show more severe encephalitis than animals only deﬁcient of T cells after inoculation with herpes
simplex virus type 1 (HSV-1) [50]. The cytotoxic function
of NK cells protects against a neurovirulent strain of the
simian immunodeﬁciency virus (SIV) in macaques [51]
and cerebral malaria in humans [52]. Also, the cytokine
production activity of NK cells is crucial against Listeria
monocytogenes neuroinvasion in mice [53], but pathogenic
during Streptococcus pneumoniae meningitis [54]. Despite
these data, studies addressing the relevance of NK cells during neuroinfections remain scarce.
In this context, our study is among the ﬁrst ones that
evaluated a possible role for NK cells during TBM in humans,
providing novel evidence for the ﬁeld. Our ﬁndings demonstrate that TBM and PTB patients showed similar phenotypical deﬁciencies in NK cells compared to LTBI individuals.
Nonetheless, TB patients with CNS infection diﬀer from
those without neuroinvasion by speciﬁc alterations in circulating NK cells’ phenotype. The most remarkable abnormality found only among TBM, but not in LTBI and PTB
patients, was the lower amounts of total and cytokineproducing CD56bright NK cells in the blood. As aforementioned, NK cells’ cytokine production is pathogenic for some
CNS bacterial infections [54]. Hence, the lack of total and
CD56bright NK cells in TBM patients may indicate, on the
one hand, that these cells migrated to the CNS. Once inside

the brain, these cells might produce proinﬂammatory cytokines that contribute to TBM patients’ brain injury and clinical manifestations. On the other hand, the reduced number
of CD56bright NK cells in the blood could be a deﬁciency that
contributes to the lack of control of Mtb infection in the lung,
thus promoting its dissemination.
Conversely, TBM patients displayed a higher amount of
cytotoxic CD56dimCD16+ NK cells in the circulation. Cytotoxicity mediated by NK cells is protective for some neurological complications of infections [51, 52], and increased
numbers of cytotoxic NK cells in the lung are a hallmark that
deﬁnes latency over active disease in macaques infected with
Mtb [28]. Thus, the increased abundance of CD56dimCD16+
NK cells in TBM patients’ blood might reﬂect an active mobilization of these cells to the CNS as an attempt to control the
local infection. In fact, CD56dimCD16+ NK cells are reduced
in the blood of human immunodeﬁciency virus- (HIV-) positive but not HIV-negative TBM patients, further supporting
a possible protective role [55]. Alternatively, protective cytotoxic NK cells could get stuck in the blood, so they cannot
move to local infection sites and contribute to eliminating
the pathogen. In this regard, van Laarhoven and colleagues
recently found that total NK cells are depleted from the blood
but enriched in the CSF of a cohort of TBM patients [56],
providing evidence that explains and coincides with some
of our ﬁndings.
Interestingly, as reported in the mentioned study [56], we
also found that NK cells from TBM patients highly express
the tissue-homing marker CD69 to a similar level than NK
cells from PTB subjects. In contrast, LTBI individuals
showed a lower expression of CD69 in peripheral NK cells.
These ﬁndings reveal that NK cells get activated and mobilize
to tissues only during active but not latent Mtb infection.
Hence, the expression of CD69 in diﬀerent cells, not only
NK cells, could be a readout that diﬀerentiates LTBI from
active pulmonary and disseminated TB disease. Notably,
although the expression of CD69 did not diﬀer between
TBM and PTB patients, a striking characteristic of our cohort
of TBM patients was the absence of clinical and radiological
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Figure 5: Memory-like NK cells in patients with TBM. (a) The percentage of CD27 NK cells in peripheral blood mononuclear cell (PBMC)
samples from healthy controls (HC, n = 10), individuals with latent TB infection (LTBI, n = 11), patients with active pulmonary TB (PTB,
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data of pulmonary involvement on hospital admission. Hence,
the expression of CD69 in NK cells during acute meningitis
reﬂects an active mobilization to the CNS in our patients, as
also reported by van Laarhoven and colleagues [56], who demonstrated that NK cells are among the main lymphoid cells
enriched in the CSF of TBM patients. Notwithstanding, their
study does not provide additional data about other phenotypical characteristics of NK cells during TBM.
Besides the main objectives of our work, we made two
ﬁndings that may have important implications in the general
understanding of anti-Mtb immunity. First, we found that,
although memory-like CD45RO+ NK cells are not more
abundant in the blood of LTBI as compared to patients with
PTB and TBM, they are more responsive to the contact with
Mtb antigens during latency. This fact has two possible
explanations: (a) that CD45RO+ NK cells are more functional and participate in protective immunity in LTBI individuals, or (b) that NK cells with adaptive properties are
depleted from the circulation of subjects with active TB as
they are recruited to the sites of local Mtb infection. An analysis of the responsiveness of CD45RO+ NK cells from
infected BAL and CSF samples would have clariﬁed this
point. However, as mentioned above, previous investigations
have already demonstrated that CD45RO+ NK cells isolated
from an active site of Mtb infection possess enhanced functional capacities [25, 26].
Secondly, we discover that higher levels of the soluble
NKG2D ligand ULBP-1 are a readout that diﬀerentiates
PTB from LTBI and TBM. This observation brings forward
the unrecognized importance of the shredding of soluble
NKGD2 ligands as an evasion mechanism of Mtb or as an
immune defect associated with poor TB control in the lungs,
but not in the CNS and during latency. This process operates
in several cancers making tumors less susceptible to the antitumoral activity of NK cells. Hence, cells infected with Mtb
might also be untargeted by NK cells keeping the intracellular
reservoir of the infection intact, at least during the disease’s
initial stages. Moreover, our ﬁndings provide novel evidence
in favor of the possible usage of serum ULBP-1 levels as a
diagnostic biomarker to diﬀerentiate LTBI and PTB, which
deserves further validation in future studies.
The main limitation of our work is the low number of
TBM patients recruited. This is because, as we mentioned
before, the incidence of this complication is low. Another
ﬂaw of this study is that we focused our analysis on peripheral blood NK cells, whereas previous investigations
addressed their properties both in the circulation and in the
local site of infection [56]. Thus, the protective or pathogenic
nature of the role of NK cells during TBM is not completely
apparent from our data. Also, additional functional assessment of NK cells would have provided complementary
mechanistic information to support the observed diﬀerences.
Finally, an important concern is that our experimental design
does not allow the evaluation of a unique NK cell TBM signature because we did not include a non-TBM extrapulmonary
TB control group.
However, as currently presented, our work represents an
incremental advance in the ﬁeld, since the phenotypical
changes of peripheral NK cells observed in our cohort of
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TBM patients with respect to LTBI and PTB individuals reafﬁrm and complement previous ﬁndings suggesting an active
role of these cells in immunity against pulmonary Mtb infection and prevention of its dissemination. Future studies
should further evaluate the main activities of NK cells in
brain tissue specimens or CSF samples from patients with
TBM and animal models of the disease.
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